Efficacy and safety of elbasvir and grazoprevir for chronic hepatitis C patients with chronic kidney disease

• Published in: Kanzo Vol. 58; no. 12; pp. 678 - 680
• Main Authors: Atsukawa, Masanori, Toyoda, Hidenori, Takaguchi, Koichi, Shimada, Noritomo, Abe, Hiroshi, Kato, Keizo, Asano, Toru, Chuganji, Yoshimichi, Mikami, Shigeru, Ogawa, Chikara, Deguchi, Akihiro, Moriya, Akio, Oryu, Makoto, Tani, Joji, Masaki, Tsutomu, Okubo, Tomomi, Arai, Taeang, Itokawa, Norio, Kondo, Chisa, Fukuda, Takeshi, Osada, Yuji, Tsubota, Akihito, Iio, Etsuko, Tanaka, Yasuhito, Kumada, Takashi
• Format: Journal Article
• Language: Japanese
• Published: The Japan Society of Hepatology 20.12.2017
• Subjects: chronic kidney disease; Elbasvir; Grazoprevir
• ISSN: 0451-4203; 1881-3593
• DOI: 10.2957/kanzo.58.678

The aim of this retrospective multicenter study was to clarify efficacy and safety of Elbasvir/Grazoprevir for chronic hepatitis C patients with chronic kidney disease (CKD). Forty-five patients with CKD were administered Elbasvir/Grazoprevir and subjected to this analysis. Overall sustained virologic response 12 rates in CKD patients were 95.6%. The sustained virologic response 4 and 12 rates were 92.9% and 92.9% in CKD G3 patients, 100% and 100% in G4 patients and 100% and 100% in G5 patients including 10 dialysis patients, respectively. The frequency of adverse event did not increase in the patients with CKD. This study suggests that Elbasvir/Grazoprevir therapy is effective and safe for genotype 1b chronic hepatitis C patients with CKD.